ProCE Banner Activity

Phase II Trial: Updated Results of Frontline Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With Untreated High-Risk CLL

Slideset Download
Conference Coverage

In a cohort of untreated patients with CLL enriched for high-risk disease, the combination of acalabrutinib, venetoclax, and obinutuzumab resulted in high response rates.

Released: December 16, 2022

Expiration: December 15, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen